Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Mavyret
|
| gptkbp:advocates_for |
aim to improve access to care
|
| gptkbp:alcohol_content |
alcohol consumption should be avoided
|
| gptkbp:associated_with |
chronic liver disease
extrahepatic manifestations |
| gptkbp:caused_by |
HCV infection
|
| gptkbp:clinical_trial |
ongoing for new treatments
disproportionately affects marginalized communities |
| gptkbp:community_impact |
affects quality of life
|
| gptkbp:complications |
liver cancer
liver cirrhosis |
| gptkbp:demographics |
more common in men
higher prevalence in certain ethnic groups |
| gptkbp:discipline |
can lead to chronic infection
|
| gptkbp:duration |
8 to 12 weeks
|
| gptkbp:economic_impact |
can lead to depression
costly to treat |
| gptkbp:education |
important for treatment adherence
|
| gptkbp:frequency |
annually for high-risk individuals
|
| gptkbp:genetic_diversity |
multiple genotypes exist
|
| gptkbp:healthcare |
elimination goals set by WHO
important in management and support recognized by WHO |
| https://www.w3.org/2000/01/rdf-schema#label |
Chronic Hepatitis C
|
| gptkbp:influenced_by |
diet and exercise recommended
|
| gptkbp:is_a_resource_for |
available for affected individuals
|
| gptkbp:is_adopted_by |
may be necessary in severe cases
|
| gptkbp:is_monitored_by |
required to check for recurrence
|
| gptkbp:is_popular_in |
approximately 71 million people worldwide
|
| gptkbp:is_protected_by |
screening of blood products
safe injection practices |
| gptkbp:is_tested_for |
elevated liver enzymes
Fibro Scan used for non-invasive assessment |
| gptkbp:is_vulnerable_to |
no vaccine available
|
| gptkbp:metabolism |
used to assess liver damage
|
| gptkbp:propagation_method |
blood-to-blood contact
|
| gptkbp:provides_information_on |
updated regularly by health organizations
access varies by region |
| gptkbp:public_awareness |
aim to reduce stigma
increased through campaigns and education. |
| gptkbp:research_focus |
new antiviral therapies
|
| gptkbp:risk_factor |
intravenous drug use
blood transfusion before 1992 |
| gptkbp:scholarships |
support groups available
|
| gptkbp:screenings |
recommended for high-risk populations
HCVRNA test used for confirmation |
| gptkbp:side_effect |
gptkb:fandom
fatigue headache nausea |
| gptkbp:sleeping_habits |
may be associated with chronic fatigue
|
| gptkbp:social_responsibility |
blood test
can last for decades HIV co-infection common often asymptomatic in early stages |
| gptkbp:supports |
may require ongoing monitoring
|
| gptkbp:symptoms |
fatigue
abdominal pain jaundice |
| gptkbp:treatment |
gptkb:drug
sustained virologic response improved with early treatment high with direct-acting antivirals |
| gptkbp:updates |
based on emerging evidence
|